Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The main objective is to evaluate the percentage of patients that do not experience progression during the first 18 weeks of treatment with Atezolizumab in patients affected by advanced solid tumors.
Critère d'inclusion
- Patients affected by histologically documented solid tumors that are advanced and have progressed following at least one line of prior systemic therapy or for which alternative therapy does not exist which is known to prolong survival.
- Please refer to the latest approved protocol version for the full list of medical conditions to be investigated